|
中国自主研发艾滋病新药有望2012年面市
2010年07月07日 17:55 来源：中国新闻网
中新网成都7月7日电 (徐杨祎 刘贤 何雨芯)7日下午，在“海外高层次人才天府行”活动现场，知名艾滋病新药研究专家谢东博士在记者采访时提到，中国自主研发艾滋病新药——全球第一个长效HIV融合抑制剂艾博卫泰已完成临床I期研究工作，预计将于2012年首先在中国上市。
据《2009年全球艾滋病流行报告》称，截止2009年12月底，中国存活的艾滋病感染者和病人将达到74万人。针对这一情况，谢东认为，目前国内防艾形势严峻，但中国自主研发艾滋病新药技术基础薄弱，进程缓慢，“研发艾滋病新药将比普通新药时间延长几年，目前国内都还属于研发阶段。”
作为全球第一个长效HIV融合抑制剂艾博卫泰的研发者，谢东告诉记者，“艾博卫泰已经完成临床I期的研究工作，将逐步进入下一阶段的临床研究，预计2012年至2013年间在中国首先面世。”
此外，谢东对中国医药产业的发展颇具信心。他说，金融危机对世界医药市场造成了很大的影响，而中国却加大了对医药市场的投入，当然市场前景就更为广阔了。中国将会成为继美国、日本之后的世界第三大医药市场。而对于当前中国生物医药行业的发展，谢东表示，“发展生物医药外包，将成为中国避免新药研发短板最直接的途径。”(完)
- 艾滋病早期治疗是康复与延长30～60年生命的保
- 艾滋病免疫重建的重要意义是挽救生命的根本
- 从食品植物研究开发的治疗艾滋病新药三合皂甙
- 康生丹颗粒免疫实验提示符合艾滋病、肿瘤等应
- 鸡尾酒疗法并非万能，抗药性与毒副作用导致联合疗法与中药疗法应用的迫切性
- 公布几例康生丹治疗艾滋病的检测报告照片
- 康生丹配合西药治疗AIDS总结
- 三合皂甙，康生丹片
- 中药康生丹治愈艾滋病中医论析
-
-
Independent research and development of AIDS drugs in China is expected to be available in 2012
At 5:55 p.m. on the July 7, 2010 Source: China News Net
BEIJING, Chengdu, July 7 (Xinhua Xu Yu Yang Yi Xian-He core) 7 pm, in the "overseas talents Tianfu" activities on site, renowned AIDS researcher Dr. Xie Dong drugs at a press interview that the Chinese self-developed AIDS drugs - the world's first long-term HIV fusion inhibitors Aibo Health Clinical I of Thailand has completed research work, is expected to be first launched in China in 2012.
According to "2009 Global AIDS Epidemic Report," and the closing by the end of December 2009, China and the survival of AIDS patients will reach 74 million. In response, Hsieh Tung believes that the current AIDS prevention situation is grim, but the Chinese self-developed AIDS drug technology foundation is weak, slow process, "development of an AIDS drug than the common drug extended a few years now there still are research and development stage. "
As the world's first HIV fusion inhibitors Aibo long-term R & D by Thai Wei, Hsieh Tung told reporters, "Aibo Wei Thailand has completed Phase I clinical study, will move into the next phase of clinical research, 2012 to 2013 published the first in China. "
In addition, Hsieh Tung-pharmaceutical industry development in China quite confident. He said the financial crisis on the pharmaceutical market in the world caused great impact, while China has increased investment in the pharmaceutical market, of course, the more extensive the market prospects. China will become the United States and Japan after the world's third largest pharmaceutical market. For the current development of Chinese bio-pharmaceutical industry, Hsieh Tung said, "Outsourcing the development of biological medicine, new drug development will become a short board to avoid the most direct route." (End)
|
